Uptakes of boronophenylalanine in the in vitro and in situ glioblastoma and the potential efficacy of boron neutron capture therapy
Human glioblastoma (GBM) is the most malignant brain tumor. Boron neutron capture therapy (BNCT) is proved to be a new technology for the effective treatment of GBM. We previously reported that boronophenylalanine (BPA), the boron drug used in BNCT prefers to the tumor of a mouse subcutaneous tumor...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-12-01
|
| Series: | IBRO Neuroscience Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667242125000971 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849424674932391936 |
|---|---|
| author | Shining Zhang Yujie Wei Wenjiao Gu Shuangyi Li Ting Liu Limei Shuai Yu Tang Ying Jiang Xiaochun Zhou Yucai Wei Guan Wang Long Gu Yumin Li Futian Tang Daiying Zuo |
| author_facet | Shining Zhang Yujie Wei Wenjiao Gu Shuangyi Li Ting Liu Limei Shuai Yu Tang Ying Jiang Xiaochun Zhou Yucai Wei Guan Wang Long Gu Yumin Li Futian Tang Daiying Zuo |
| author_sort | Shining Zhang |
| collection | DOAJ |
| description | Human glioblastoma (GBM) is the most malignant brain tumor. Boron neutron capture therapy (BNCT) is proved to be a new technology for the effective treatment of GBM. We previously reported that boronophenylalanine (BPA), the boron drug used in BNCT prefers to the tumor of a mouse subcutaneous tumor model injected U87 and GL261, two GBM cell lines. The present study was designed to investigate the distribution of BPA in the tumor of a mouse in situ brain tumor model injected U87 and GL261 in the brain. The tumor model was evaluated by using small animal magnetic resonance imaging (MRI) and confirmed with the morphological observations. The boron concentration indicative of BPA in cells and tumor was measured using inductively coupled plasma atomic emission spectroscopy (ICP-AES). The results revealed that the protein of L-type amino acid transporter (LAT1) was highly expressed in both U87 and GL261 cells. In addition, boron concentration in U87 and GL261 cells was increased 1, 2, 3, 5 and 7 h after addition of BPA in a time-dependently manner. However, the boron concentration in the cells was rapidly decreased when the BPA in the medium was withdrawn for 1 h at each time point, reaching almost the same levels between the time points. In one mouse in situ brain tumor model injected U87 cells, the concentration of boron in the tumor tissue (25.529 μg/g) was higher than that in brain tissue (8.973 μg/g), blood (11.407 μg/g), heart (13.131 μg/g), liver (11.271 μg/g), spleen (15.631 μg/g) and lung (16.226 μg/g) respectively, having ratios of tumor/normal tissue 2.845, 2.238, 1.944, 2.265, 1.633 and 1.537 respectively. Similarly, in another mouse in situ brain tumor model injected GL261 cells, the concentration of boron in the tumor tissue (23.039 μg/g) was higher than that in brain tissue (8.141 μg/g), blood (9.573 μg/g), heart (12.119 μg/g), liver (9.609 μg/g), spleen (15.852 μg/g) and lung (12.565 μg/g) respectively, having ratios of tumor/normal tissue 2.831, 2.407, 1.901, 2.398, 1.453 and 1.834 respectively. The results suggest that uptakes of BPA in two cell lines occur in a time-dependent manner and that BPA preferred to distribute in brain tumor tissue than other normal tissues, having potential efficacy of BNCT. |
| format | Article |
| id | doaj-art-476f1955c5904feb92ebfc12febe46c8 |
| institution | Kabale University |
| issn | 2667-2421 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | IBRO Neuroscience Reports |
| spelling | doaj-art-476f1955c5904feb92ebfc12febe46c82025-08-20T03:30:04ZengElsevierIBRO Neuroscience Reports2667-24212025-12-011919219710.1016/j.ibneur.2025.06.014Uptakes of boronophenylalanine in the in vitro and in situ glioblastoma and the potential efficacy of boron neutron capture therapyShining Zhang0Yujie Wei1Wenjiao Gu2Shuangyi Li3Ting Liu4Limei Shuai5Yu Tang6Ying Jiang7Xiaochun Zhou8Yucai Wei9Guan Wang10Long Gu11Yumin Li12Futian Tang13Daiying Zuo14College of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang 110016, China; Gansu Province Key Laboratory of Environmental Oncology, Lanzhou University Second Hospital, Lanzhou 730030, China; School of Nuclear Science and Technology, Lanzhou University, Lanzhou, ChinaGansu Province Key Laboratory of Environmental Oncology, Lanzhou University Second Hospital, Lanzhou 730030, ChinaDepartment of Cardiovascular Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, ChinaDepartment of Cardiovascular Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, ChinaSchool of Basic Medical Sciences, Lanzhou University, Lanzhou 730030, ChinaSchool of Basic Medical Sciences, Lanzhou University, Lanzhou 730030, ChinaClinical Medicine Department, Xinxiang Medical University, Xinxiang 453003, ChinaDepartment of Cardiovascular Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, ChinaDepartment of Nephrology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, ChinaGansu Province Key Laboratory of Environmental Oncology, Lanzhou University Second Hospital, Lanzhou 730030, ChinaSchool of Nuclear Science and Technology, Lanzhou University, Lanzhou, ChinaSchool of Nuclear Science and Technology, Lanzhou University, Lanzhou, ChinaGansu Province Key Laboratory of Environmental Oncology, Lanzhou University Second Hospital, Lanzhou 730030, ChinaGansu Province Key Laboratory of Environmental Oncology, Lanzhou University Second Hospital, Lanzhou 730030, China; Department of Cardiovascular Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China; Corresponding author at: Gansu Province Key Laboratory of Environmental Oncology, Lanzhou University Second Hospital, Lanzhou 730030, China.College of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang 110016, China; Corresponding author.Human glioblastoma (GBM) is the most malignant brain tumor. Boron neutron capture therapy (BNCT) is proved to be a new technology for the effective treatment of GBM. We previously reported that boronophenylalanine (BPA), the boron drug used in BNCT prefers to the tumor of a mouse subcutaneous tumor model injected U87 and GL261, two GBM cell lines. The present study was designed to investigate the distribution of BPA in the tumor of a mouse in situ brain tumor model injected U87 and GL261 in the brain. The tumor model was evaluated by using small animal magnetic resonance imaging (MRI) and confirmed with the morphological observations. The boron concentration indicative of BPA in cells and tumor was measured using inductively coupled plasma atomic emission spectroscopy (ICP-AES). The results revealed that the protein of L-type amino acid transporter (LAT1) was highly expressed in both U87 and GL261 cells. In addition, boron concentration in U87 and GL261 cells was increased 1, 2, 3, 5 and 7 h after addition of BPA in a time-dependently manner. However, the boron concentration in the cells was rapidly decreased when the BPA in the medium was withdrawn for 1 h at each time point, reaching almost the same levels between the time points. In one mouse in situ brain tumor model injected U87 cells, the concentration of boron in the tumor tissue (25.529 μg/g) was higher than that in brain tissue (8.973 μg/g), blood (11.407 μg/g), heart (13.131 μg/g), liver (11.271 μg/g), spleen (15.631 μg/g) and lung (16.226 μg/g) respectively, having ratios of tumor/normal tissue 2.845, 2.238, 1.944, 2.265, 1.633 and 1.537 respectively. Similarly, in another mouse in situ brain tumor model injected GL261 cells, the concentration of boron in the tumor tissue (23.039 μg/g) was higher than that in brain tissue (8.141 μg/g), blood (9.573 μg/g), heart (12.119 μg/g), liver (9.609 μg/g), spleen (15.852 μg/g) and lung (12.565 μg/g) respectively, having ratios of tumor/normal tissue 2.831, 2.407, 1.901, 2.398, 1.453 and 1.834 respectively. The results suggest that uptakes of BPA in two cell lines occur in a time-dependent manner and that BPA preferred to distribute in brain tumor tissue than other normal tissues, having potential efficacy of BNCT.http://www.sciencedirect.com/science/article/pii/S2667242125000971Boron neutron capture therapyBoronophenylalanineBrain tumor cell linesIn situ brain tumor modelBoron distribution |
| spellingShingle | Shining Zhang Yujie Wei Wenjiao Gu Shuangyi Li Ting Liu Limei Shuai Yu Tang Ying Jiang Xiaochun Zhou Yucai Wei Guan Wang Long Gu Yumin Li Futian Tang Daiying Zuo Uptakes of boronophenylalanine in the in vitro and in situ glioblastoma and the potential efficacy of boron neutron capture therapy IBRO Neuroscience Reports Boron neutron capture therapy Boronophenylalanine Brain tumor cell lines In situ brain tumor model Boron distribution |
| title | Uptakes of boronophenylalanine in the in vitro and in situ glioblastoma and the potential efficacy of boron neutron capture therapy |
| title_full | Uptakes of boronophenylalanine in the in vitro and in situ glioblastoma and the potential efficacy of boron neutron capture therapy |
| title_fullStr | Uptakes of boronophenylalanine in the in vitro and in situ glioblastoma and the potential efficacy of boron neutron capture therapy |
| title_full_unstemmed | Uptakes of boronophenylalanine in the in vitro and in situ glioblastoma and the potential efficacy of boron neutron capture therapy |
| title_short | Uptakes of boronophenylalanine in the in vitro and in situ glioblastoma and the potential efficacy of boron neutron capture therapy |
| title_sort | uptakes of boronophenylalanine in the in vitro and in situ glioblastoma and the potential efficacy of boron neutron capture therapy |
| topic | Boron neutron capture therapy Boronophenylalanine Brain tumor cell lines In situ brain tumor model Boron distribution |
| url | http://www.sciencedirect.com/science/article/pii/S2667242125000971 |
| work_keys_str_mv | AT shiningzhang uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT yujiewei uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT wenjiaogu uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT shuangyili uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT tingliu uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT limeishuai uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT yutang uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT yingjiang uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT xiaochunzhou uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT yucaiwei uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT guanwang uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT longgu uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT yuminli uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT futiantang uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy AT daiyingzuo uptakesofboronophenylalanineintheinvitroandinsituglioblastomaandthepotentialefficacyofboronneutroncapturetherapy |